Rocket Pharma reports Q4 2022 net loss of $66.7M; cash $399.7M; pipeline on track for 2023 regulatory filings

ROCKET PHARMACEUTICALS, INC.

2022-FY EPS reported -$3.26

Net loss $66.7M ($0.92/sh) in Q4 2022 vs $44.2M ($0.69) in Q4 2021; full-year net loss $221.9M ($3.26) vs $169.1M ($2.67).
Cash, cash equivalents and investments $399.7M as of Dec 31, 2022; expected runway through 2024.
Plans BLA submissions: LAD-I in Q2 2023, Fanconi Anemia in Q4 2023; Phase 2 pivotal for Danon Disease (RP-A501) starts Q2 2023.
FDA granted RMAT designation for RP-A501 (Danon Disease); acquired Renovacor in Dec 2022 adding BAG3-DCM program.
Raised $197.7M in 2022 via follow-on, ATM, and Renovacor cash; appointed new board member and executives.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ROCKET PHARMACEUTICALS, INC. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 27, 2023, Rocket Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-008940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.